Experimental Therapeutics

项目摘要/摘要 实验治疗(ET)计划的研究重点是识别、开发和测试 新的癌症疗法。这是通过以1)为中心的三个重叠的具体目标来实现的 确定潜在靶点并发现治疗线索，2)进行临床前评估 有前景的新治疗方法，以及3)评估创新和有前景的药物、组合和 临床试验中监测反应的方法。ET调查人员高度合作。关键科学 ET研究人员在前一个资助期取得的成就包括发现新的治疗方法 子宫内膜癌和骨髓瘤的靶点，纳米药物开发，癌症免疫治疗 基于Toll样受体(TLR9)激动剂，使用药物抗坏血酸来增强疗效和 减少化疗和放射治疗的毒性(与fRMI方案合作)，以及 扩大研究人员发起和第一阶段的能力，包括肿瘤内治疗的试验。有28个 ET的正式成员和16名准成员，包括实验室、翻译和临床研究人员 横跨五所学院的13个系。年度同行评审的癌症直接成本最高 最近的预算年度为270万美元(NCI为190万美元)。额外资金包括380万美元用于 未经同行评审的研究项目。ET成员具有高度的协作性，曾撰写或共同撰写 在过去五年中发表了291篇与癌症有关的同行评议出版物，其中24%(n=69)在方案内发表，43% (n=124)跨计划出版物，42%(n=123)跨机构出版物。29篇稿件 出现在高影响力期刊上(影响系数≥10)。

PROJECT SUMMARY/ABSTRACT Research in the Experimental Therapeutics (ET) program focuses on identification, development and testing of new cancer therapeutics. This is accomplished through three overlapping specific aims centered on 1) identifying potential targets and discovering therapeutics leads, 2) conducting preclinical evaluation of promising new therapeutic approaches, and 3) evaluating innovative and promising agents, combinations, and approaches to monitoring response in clinical trials. ET investigators are highly collaborative. Key scientific achievements of ET investigators over the prior funding period include identification of novel therapeutic targets in endometrial cancer and myeloma, nanoparticle based drug development, cancer immunotherapy based on toll-like receptor (TLR9) agonists, use of pharmacologic ascorbate to enhance the efficacy and reduce the toxicity of both chemotherapy and radiation therapy (in collaboration with the FRMI Program), and expansion of investigator-initiated and Phase I capabilities including trials of intralesional therapy. There are 28 full and 16 associate members of ET including laboratory-based, translational and clinical investigators spanning 13 departments across five colleges. Annual total peer-reviewed cancer direct costs in the most recent budget year was $2.7 million ($1.9 million from the NCI). Additional funding included $3.8 million for non-peer-reviewed research projects. ET members are highly collaborative having authored or co-authored 291 cancer-related peer-reviewed publications in the past five years, with 24% (n= 69) intraprogrammatic, 43% (n= 124) interprogrammatic, and 42% (n= 123) interinstitutional publications. Twenty-nine manuscripts appeared in high impact journals (Impact Factor ≥10).